SPS
MRSN

Susquehanna Portfolio Strategies’s Mersana Therapeutics MRSN Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,309
Closed -$156K – 214
2024
Q3 		$156K Sell
3,309
-446
-12% -$19.7K 0.01% 324
2024
Q2 		$189K Hold
3,755
– – 0.01% 471
2024
Q1 		$421K Hold
3,755
– – 0.01% 619
2023
Q4 		$218K Buy
+3,755
New +$151K ﹤0.01% 930

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Susquehanna Portfolio Strategies's MRSN Position: Q4 2024 in Review

Susquehanna Portfolio Strategies sold out of Mersana Therapeutics (MRSN) in Q4 2024, closing a stake of 3,309 shares — an estimated $156K sold.

Susquehanna Portfolio Strategies first reported a position in MRSN in Q4 2023 and held it in 4 quarters. The position peaked at $421K in Q1 2024. 128 funds tracked by Wall St. Rank hold MRSN as of Q4 2024.

  • Susquehanna Portfolio Strategies reported no remaining Mersana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 3,309 Mersana Therapeutics shares in Q4 2024, an estimated $156K.
  • Susquehanna Portfolio Strategies first reported a position in Mersana Therapeutics in Q4 2023 and held it in 4 quarters.
  • Susquehanna Portfolio Strategies's Mersana Therapeutics position peaked at $421K in Q1 2024.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2024.

Based on Susquehanna Portfolio Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.